Similar parameters, as used in the RESET-RA study [Levine et al., 2020; Peterson et al., 2024] could be used for the proposed trial in patients with glioblastoma as the objective is to reduce systemic inflammation, the “inflammatory reflex,” and lower IL-6 to non-detectable levels or barely detectable, normal (<5–10 pg/mL) levels, which can be influenced by age, gender, depression or stress [Sullivan et al., 2018; Bremner et al., 2020]. The gene discussed is IL6; the disease is depressive disorder.